Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Side-by-side look at the strengths and weaknesses of zero-based budgeting and envelope systems to help you decide which suits your goals.
28,655 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Solana just overtook Ethereum in developer signups, marking a major shift in blockchain mindshare. The latest data po...
The SPDR Russell 1000 Yield Focus ETF nears a $125 price point, anchored by Johnson & Johnson and other blue-chip div...
A pre-retiree left for a rival firm and forfeited $74,000 in 401(K) employer matching by missing the vesting cliff. T...
A renewed bond market selloff is sharpening focus on fiscal risks. Analysts say the u.s. debt ‘elephant room’ could q...
Bitcoin again hovers near the 70K mark as XRP mirrors BTC moves. A test of AI forecasting asks what XRP bottoms could...
Broadcom posted a solid quarter but guided toward softer AI chip sales, sending its stock lower and dragging peers li...
A federally funded health study tied to the Biden administration finds no safe level of alcohol and warns risks rise ...
As market volatility persists into mid-2026, a single calculation could alter when you claim Social Security. Get the...
Morningstar analysts warn SpaceX could be worth far less than its IPO price, focusing on profitability gaps and Starl...
Think you need a premium card to unlock great travel perks? Think again. This guide shows the advantages of low annua...
A fresh analysis shows WisdomTree's WCLD underperforms due to equal-weight rebalancing, turning a $10,000 stake into ...